Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 15/01/2014 20872_de.jpg

    Hit Discovery Constance GmbH: a new hub for HTS and compound management

    Hit Discovery Constance GmbH (“HDC”), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance (Germany) and will make use of the already established equipment and know-how of the former Takeda/Nycomed/Altana screening and compound management facilities at the site.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/hit-discovery-constance-gmbh-a-new-hub-for-hts-and-compound-management
  • Article - 14/01/2013 19037_de.jpg

    Boehringer takes a deep breath: a look into the company’s respiratory R&D pipeline

    At its 3rd International Research & Development (R&D) press conference, Boehringer Ingelheim gave journalists insights into its R&D pipeline. Around 200 scientists at the company’s site in Biberach are investigating new treatment options for patients with COPD (chronic obstructive pulmonary disease), asthma, idiopathic lung fibrosis, lung cancer and other respiratory diseases. In addition, the researchers are also focusing on the…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/boehringer-takes-a-deep-breath-a-look-into-the-company-s-respiratory-r-d-pipeline
  • Article - 07/01/2013 19006_de.jpg

    HepaChip: a promising tool for assessing adverse drug effects

    Liver damage is one of the most common adverse drug effects. Since results obtained with animal experiments can only be transferred to the situation in humans to a limited extent, there is a need for cell-based systems that model human organ function as closely as possible. The new HepaChip, developed by researchers at the NMI in Reutlingen on the basis of human liver and endothelial cells is able to do just this.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/hepachip-a-promising-tool-for-assessing-adverse-drug-effects
  • Press release - 18/12/2012 Phenex Logo

    Phenex enters into a research collaboration and license agreement with Janssen

    Phenex Pharmaceuticals AG Phenex today announced it has entered into an agreement with Janssen Biotech Inc. and its affiliates Janssen to jointly discover compounds that target the nuclear hormone receptor RORT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis psoriasis and inflammatory bowel disease.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/phenex-enters-into-a-research-collaboration-and-license-agreement-with-janssen
  • Article - 17/12/2012 18972_de.jpg

    rent-a-lab – the bioassay specialist

    rent-a-lab has been offering services to detect and determine the quantity of biomolecules for around ten years. The company is mainly focused on studies related to the binding of biomolecules to GTP-binding protein-coupled receptors, a field that has attracted a great deal of attention following the award of the Nobel Prize in Chemistry 2012 for the identification of this important class of receptors.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/rent-a-lab-the-bioassay-specialist
  • Article - 03/12/2012 18832_de.jpg

    Targeted therapeutic approaches that revolutionise melanoma treatment

    Melanoma is difficult to treat once it has spread from the skin to other parts of the body. Classical chemotherapy is often ineffective and the majority of patients die within a few months after diagnosis. However, the biggest breakthrough in around 30 years has now been achieved with the development of kinase inhibitors that directly interfere with the cancer cells’ molecular signalling pathways. Clinical research into the application of kinase…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/targeted-therapeutic-approaches-that-revolutionise-melanoma-treatment
  • Press release - 13/11/2012 18685_de.jpg

    immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment

    immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-renal-cancer-vaccine-ima901-completes-phase-3-patient-recruitment
  • Press release - 09/11/2012 Logo apogenix

    Apogenix’s Apocept™ for glioblastoma multiforme named one of “Top 10 Projects to Watch”

    Apogenix a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases announced that its lead product Apocept APG101 has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncologys Top 10 Projects To Watch.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-s-apocept-for-glioblastoma-multiforme-named-one-of-top-10-projects-to-watch
  • Press release - 02/10/2012 18294_de.jpg

    Making cell division impossible: Optimized substance forces cancer cells into death

    Many tumor cells have a defective cellular equipment. It is only by a special trick that they manage to distribute their chromosomes correctly to their daughter cells during cell division. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now developed a substance that thwarts this trick and forces cancer cells into death during cell division. The group has now reported their results in the journal…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/making-cell-division-impossible-optimized-substance-forces-cancer-cells-into-death
  • Press release - 21/08/2012 17950_de.jpg

    Freiburg research team sheds light on important metabolite in bacteria

    Scientists from the research groups of Prof. Dr. Susana Andrade and Prof. Dr. Oliver Einsle, members of the Institute of Organic Chemistry and BIOSS Centre for Biological Signalling Studies, Cluster of Excellence of the University of Freiburg, have collected the first precise data ever on the function of a transport protein for formate – an important metabolite in bacteria. The findings could potentially lead to the development of new antibiotic…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/freiburg-research-team-sheds-light-on-important-metabolite-in-bacteria
  • Press release - 08/08/2012 Logo apogenix

    Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial

    The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
  • Press release - 25/10/2011 15652_de.jpg

    Research Initiative to Combat Cell Ageing

    Insilico Biotechnology and its partners have started a joint large-scale research project to study how reactive oxygen species trigger ageing processes on the cell and tissue level and how to prevent these if possible. Biomarkers will be used to expose the processes and molecular target structures will be identified which can be targeted with active agents to delay ageing.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/research-initiative-to-combat-cell-ageing
  • Article - 25/07/2011 14863_de.jpg

    Cell culturing as a taught subject: many more “Biberachs” are needed

    Cell culture technology is only taught at a handful of universities. However, this interdisciplinary subject is the core of the “Pharmaceutical Biotechnology” programme offered by the Biberach University of Applied Sciences. We talked about the subject with Professor Jürgen Hannemann, founding dean of the “Pharmaceutical Biotechnology” programme, and with Professor Friedemann Hesse, who runs the “cell culture technology” teaching programme.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/cell-culturing-as-a-taught-subject-many-more-biberachs-are-needed
  • Article - 16/05/2011 14307_de.jpg

    New analysis tools involving molecularly imprinted polymers

    The demand for made-to-measure analytical methods is increasing as interest in the biological production of materials and pharmaceuticals increases. It is extremely important economically for bioindustry to know the production time and quantity of products that result from specific fermentation conditions. Inspired by natural molecular processes, researchers from Tübingen and Stuttgart are working on new, label-free analytical methods that make…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-analysis-tools-involving-molecularly-imprinted-polymers
  • Press release - 16/11/2010 12926_de.jpg

    Nycomed is keeping the pace in third quarter 2010 - US Food & Drug Administration to decide on the approval of Daxas®

    Nycomed’s strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole. Daxas® (roflumilast) has recently been launched in the first EU markets and further launches are underway over the coming months. To accelerate the expansion in China, one of the fastest…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-is-keeping-the-pace-in-third-quarter-2010-us-food-drug-administration-to-decide-on-the-appro
  • Press release - 20/05/2008

    A promising start into 2008

    In the first quarter of 2008 Nycomeds adjusted EBITDA increased by 6.2 to 304.0 million compared to 286.3 million in the first quarter of 2007 benefiting from the cost decreasing effects of last years restructuring.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/a-promising-start-into-2008
  • Article - 19/03/2008

    Nycomed intends to move chemical production to Indian joint venture

    Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India. Based on this agreement, Nycomed plans to transfer the current chemical production from the sites in Linz (Austria) and Singen (Germany) to the new joint venture within the next three to four…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-intends-to-move-chemical-production-to-indian-joint-venture

Page 3 / 3

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search